Neuphoria Therapeutics Inc.

Neuphoria Therapeutics Inc.

NEUP
Neuphoria Therapeutics Inc.US flagNASDAQ Global Market
Capital Structure

in mil. unless spec.
Working Capital

in mil. unless spec.
Growth Rates

in mil. unless spec.
Quarterly Revenue

in mil. unless spec.
Quarterly Earnings Per Share

in mil. unless spec.
Quarterly Dividends Per Share

in mil. unless spec.

Company Description

CEO
Spyridon Papapetropoulos
Full Time Employees
24
Sector
Healthcare
Industry
Medical - Pharmaceuticals
Address
Burlington United States of America
IPO Date
Dec 16, 2021
Similar Companies
Business
Neuphoria Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.

Company News

  • Neuphoria Therapeutics Inc. to Receive $15M Milestone Payment from Merck

  • Here's Why Momentum in Neuphoria Therapeutics Inc. (NEUP) Should Keep going

  • Neuphoria Completes Re-domiciliation and Successor Listing on Nasdaq